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Portal venous thrombosis (PVT) may be primary or
secondary in origin [1–4]. Secondary PVT can be caused
by various acquired disorders such as antithrombin III
deficiency, sepsis, disseminated intravascular coagula-
tion, intra-abdominal infectious or inflammatory condi-
tions, liver cirrhosis, surgical intervention, or abdominal
malignancies such as pancreatic or hepatocellular
carcinoma (HCC). Symptom development in PVT is
often insidious and related to the progression of por-
tal hypertension which can lead to hemorrhage from
esophageal or cardiac varices. Moreover, malignant
PVT can cause wide dissemination of cancer cells. Man-
agement of PVT should be based on its etiology and
the condition of the patient, e.g. anticoagulation ther-
apy for benign PVT, and treatment of underlying cancer
for malignant PVT. However, the side effects of treat-
ment cannot be tolerated by some of these patients.
In this case report, a cirrhotic patient with HCC suffered
from acute pancreatitis complicated with transient PVT
in the main trunk. Our experience may provide useful
information for the management of such patients.
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Portal venous thrombosis (PVT) is a condition associated with high morbidity. The etiologies 
of PVT include intra-abdominal inflammation or infection, surgical intervention, abdominal malig-
nancies such as hepatocellular carcinoma (HCC) and pancreatic carcinoma, or abnormality in
coagulation caused by various reasons such as liver cirrhosis. Management of PVT should be
based on its etiology and the condition of the patient. We describe a cirrhotic patient with HCC
who suffered from acute pancreatitis. PVT in the main trunk was detected at admission due to the
episode of acute pancreatitis. The etiology of thrombosis was considered to be inflammation around
the main portal trunk caused by pancreatitis rather than cirrhosis or HCC. We did not instigate
any management for the thrombosis. Acute pancreatitis was relieved after conservative treatment.
Follow-up imaging study performed 46 days after detection of thrombosis showed spontaneous
complete resolution of the thrombus. Our experience may provide useful information for the
management of such patients.
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CASE PRESENTATION
The patient was a 33-year-old man with HCC and
liver cirrhosis caused by chronic hepatitis B virus infec-
tion. Multiple nodular type HCC was diagnosed based
on high serum α-fetoprotein (AFP) level (3,296ng/mL;
normal < 20 ng/mL) [5] and imaging studies [6] in
December 2004. He received three sessions of trans-
catheter arterial chemoembolization and one session
of percutaneous pure ethanol injection for the man-
agement of HCC. The functional reserve of liver 
cirrhosis was maintained in Child–Pugh class A.
Serum AFP level returned to within normal range
after this treatment, but it rebounded to 165.9 ng/mL
on March 22, 2006.
Serial imaging studies including whole body
bone scan, chest X-ray, abdominal ultrasonography,
magnetic resonance imaging and angiography were
performed to detect the possibility of recurrent HCC.
However, no definite viable HCC was found. The
serum AFP level increased to 422 ng/mL on June 7,
2006. The condition of the patient was quite satis-
factory until June 25, 2006 when he suffered severe
abdominal pain and was sent to our emergency de-
partment. The characteristics of the pain were dull,
radiating to the back, aggravated by food intake and
relieved by bed rest. The location of the pain was
around the epigastric area. Physical examination
showed diffuse abdominal tenderness, diminished
bowel sounds but no rebounding pain or fever. Labo-
ratory data showed serum C-reactive protein 15.32μg/
mL (normal < 5 μg/mL), amylase 308 U/L (normal 
<123 U/L), lipase 284 IU/L (normal<58 IU/L), aspar-
tate aminotransferase 51 U/L (normal < 35 U/L), ala-
nine aminotransferase 66 U/L (normal<92 U/L), total
bilirubin 2.13 mg/dL (normal<1.11 mg/dL), and con-
jugated bilirubin 1.17 mg/dL (normal < 0.4 mg/dL).
The coagulation profile was: prothrombin time, 11.6
seconds/10.7 seconds (control); international normal-
ized ratio, 1.05; partial prothrombin time, 33.4 seconds/
30.1 seconds (control).
Under the impression of acute pancreatitis, contrast-
enhanced computed tomography (CT) was performed.
Peripancreatic fluid collection around the pancreatic
head was found, which supported the diagnosis 
of pancreatitis. Moreover, CT also showed deposition
of lipiodol caused by previous transcatheter arterial
chemoembolization in segments 3 and 6 by Couinaud
Segmental Classification [7], suspected dysplastic
nodules in segments 5 and 6 [7], liver cirrhosis with
splenomegaly, gallbladder stones, main portal trunk
thrombosis, and ascites (Figure 1).
He was admitted to our institution for the treat-
ment of acute pancreatitis. The general condition of
the patient improved rapidly after conservative man-
agement and he was discharged 9 days later. Reserve
liver function did not deteriorate during admission.
The main portal trunk thrombosis was not treated
because thrombosis was considered to be caused by
local inflammation during the episode of pancreatitis
and observation was advised.
Unfortunately, he suffered from another similar
episode of severe abdominal pain on August 10, 2006.
The characteristics of the pain were dull, radiating to
the back, aggravated by food intake and relieved by
bed rest. The location of the pain was around the epi-
gastric area. Physical examination showed diffuse ab-
dominal tenderness, decreased bowel sounds but no
rebounding pain or fever. Laboratory data showed an
elevated serum lipase level (215 IU/L). Under the
impression of acute pancreatitis, contrast-enhanced
CT was again performed. Compared to the previous
study, the amount of ascites had slightly increased.
The sizes of the hepatic nodules remained unchanged
and the main portal trunk was free of thrombosis
Figure 1. Contrast-enhanced computed tomography in this slice
showed peripancreatic fluid collection (arrow) around the pancre-
atic head and thrombosis of the main portal trunk (arrowhead)
that was not detected by magnetic resonance imaging performed 
1 month previously. This slice also showed deposition of lipiodol
in segments 3 and 6, a suspected dysplastic nodule in segment 6,
liver cirrhosis with splenomegaly and collateral circulation at the
splenic hilum and perigastric region.
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(Figure 2). He was admitted to our institution for
conservative treatment of acute pancreatitis and dis-
charged 7 days later.
DISCUSSION
Liver cirrhosis plays an important role in adult patients
with PVT. Splenomegaly, wide main portal trunk,
high portal venous pressure and the terminal stage of
liver function are reported to be risk factors for the
development of PVT in patients with cirrhosis [8,9].
However, the actual mechanism for the development
of PVT in patients with cirrhosis still needs to be 
clarified [10]. It has been reported that a decrease in
portal blood flow and the presence of peripheral lym-
phangitis and fibrosis may be associated with the devel-
opment of PVT [11]. Reduced liver synthetic activity
made the coagulation and anticoagulation factors
abnormal in patients with liver cirrhosis [12]. Abnor-
mality in coagulation can be a precipitating factor for
the development of PVT.
Neoplasm is another important cause of the devel-
opment of PVT. Among malignancies causing PVT,
HCC and pancreatic carcinoma are the two most fre-
quent causes [13]. The mechanisms for the develop-
ment of PVT in malignancy can be due to the invasion
of cancer cells to the portal lumen, compression of the
portal vein by tumor burden, or by neoplasm-related
prothrombotic changes [14].
Management of PVT should be based on its etiology
and the condition of the patient. Spontaneous resolu-
tion of PVT caused by benign etiology is possible but
uncommon [13]. Anticoagulation therapy is recom-
mended for the treatment of acute benign PVT as com-
plete or partial resolution can be achieved in up to 80%
of patients [15]. Heparin and tissue-type plasminogen
activator (t-PA) are used in most studies [15–17]. Anti-
coagulation may not increase the risk of bleeding but
reduces that of mesenteric infarction, which is possi-
bly life-threatening. However, systemic anticoagula-
tion therapy may be unsuitable for cirrhotic patients
with severe abnormality in coagulation. Thrombolysis
through a transhepatic route is another choice for the
treatment of acute benign PVT to avoid the adverse
effects of systemic anticoagulant therapy [17–19]. This
is an invasive management and carries the risk of intra-
abdominal hemorrhage or hemobilia. The management
of PVT caused by malignancy is quite different from
that used for the management of benign PVT. The res-
olution of malignant PVT can be achieved only when
the involved cancer cells can be well treated. Systemic
chemotherapy, local irradiation therapy, or transcath-
eter arterial chemoembolization are choices for the
management of malignant PVT. However, each of the
above carries its own side effects and cannot be applied
to all patients with malignant PVT.
The case presented above had HCC and cirrhosis,
both of which could possibly develop to PVT. Progres-
sive increase in serum AFP levels during the follow-
up period strongly suggested recurrence of HCC.
Therefore, new-onset PVT detected by CT was rea-
sonably considered to be malignant in origin. However,
the location of PVT was in the main trunk. There was
no detectable hepatofugal portal flow in imaging stud-
ies and the other parts of the portal system were com-
pletely free of thrombosis. The locations of all treated
HCC nodules and the suspected dysplastic nodules
were far away from the main trunk thrombus. There
was also no detectable tumor burden around the main
portal trunk. PVT in this case was not considered to
be caused by HCC. On the other hand, the possibility
of PVT caused by cirrhosis could not be completely
excluded. However, this case did not have past history
of abnormality in coagulation. Sudden onset of throm-
bosis located only in part of the main trunk was not
easily explained by the reason of abnormality in coag-
ulation. Pancreatitis is a possible etiology of PVT. The
mechanism is suggested to be either portal venous
Figure 2. Compared to the previous contrast-enhanced computed
tomography, the amount of peripancreatic fluid collection (arrow)
around the pancreatic head had decreased, but ascites had slightly
increased. The main portal trunk was free of thrombosis (arrowhead).
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compression caused by pseudocyst or abscess, or an
imbalance between blood coagulation and fibrinolysis
[19]. Portal phlebitis caused by leakage of pancreatic
juice around the portal vein may also be a factor in
the development of PVT in pancreatitis. The location
of thrombus in this case was surrounded by the fluid
induced by the episode of pancreatitis. Formation of
thrombus caused by local phlebitis was the most rea-
sonable explanation in this case. PVT can elevate the
portal pressure which had the potential to cause rup-
ture of esophageal or cardiac varices. In this case, we
did not examine the change in portal pressure or varices
during admission, because there was no evidence of
gastrointestinal hemorrhage to support the necessity
of performing further examination. We did not treat
the PVT and chose close observation instead. Disap-
pearance of thrombus soon after recovery from acute
pancreatitis confirmed that PVT was caused by the
inflammatory process. The second episode of acute
pancreatitis did not show evidence of PVT. This could
be explained by fluid collection around the main trunk
in the second episode being much less than that in the
first episode. Two episodes of acute pancreatitis could
be successfully treated by a conservative approach. No
obvious cause of pancreatitis could be identified by
imaging studies, patient drug abuse history, or labo-
ratory data. Although the imaging studies did not show
any evidence of biliary stones, according to the clini-
cal course of this patient, pancreatitis caused by pas-
sage of common bile stones combined with or without
cholangitis was the most likely etiology.
In conclusion, PVT can be caused by pancreatitis.
Control of the underlying disease may be the first
choice for treatment of this kind of PVT. Development
of PVT in a patient with HCC and cirrhosis necessarily
originates from one of these two possible etiologies
and the other possibilities should also be considered.
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